Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model

Siegel, 2013, Cancer statistics, 2013, CA Cancer J Clin, 63, 11, 10.3322/caac.21166 Bokhman, 1983, Two pathogenetic types of endometrial carcinoma, Gynecol Oncol, 15, 10, 10.1016/0090-8258(83)90111-7 Amant, 2005, Endometrial cancer, Lancet, 366, 491, 10.1016/S0140-6736(05)67063-8 Hamilton, 2006, Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers, Br J Cancer, 94, 642, 10.1038/sj.bjc.6603012 Boruta, 2009, Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review, Gynecol Oncol, 115, 142, 10.1016/j.ygyno.2009.06.011 del Carmen, 2012, Uterine papillary serous cancer: a review of the literature, Gynecol Oncol, 127, 651, 10.1016/j.ygyno.2012.09.012 Artavanis-Tsakonas, 1999, Notch signaling: cell fate control and signal integration in development, Science, 284, 770, 10.1126/science.284.5415.770 Bray, 2006, Notch signalling: a simple pathway becomes complex, Nat Rev Mol Cell Biol, 7, 678, 10.1038/nrm2009 Kopan, 2009, The canonical Notch signaling pathway: unfolding the activation mechanism, Cell, 137, 216, 10.1016/j.cell.2009.03.045 McAuliffe, 2012, Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy, Proc Natl Acad Sci U S A, 109, E2939, 10.1073/pnas.1206400109 Avila, 2013, Notch signaling in pancreatic cancer: oncogene or tumor suppressor?, Trends Mol Med, 19, 320, 10.1016/j.molmed.2013.03.003 Park, 2006, Notch3 gene amplification in ovarian cancer, Cancer Res, 66, 6312, 10.1158/0008-5472.CAN-05-3610 Chen, 2012, Defining NOTCH3 target genes in ovarian cancer, Cancer Res, 72, 2294, 10.1158/0008-5472.CAN-11-2181 2011, Integrated genomic analyses of ovarian carcinoma, Nature, 474, 609, 10.1038/nature10166 Mori, 2012, Diagnostic utility of notch-1 immunocytochemistry in endometrial cytology, Acta Cytol, 56, 166, 10.1159/000335485 Mitsuhashi, 2012, Prognostic significance of Notch signalling molecules and their involvement in the invasiveness of endometrial carcinoma cells, Histopathology, 60, 826, 10.1111/j.1365-2559.2011.04158.x Cobellis, 2008, The pattern of expression of Notch protein members in normal and pathological endometrium, J Anat, 213, 464, 10.1111/j.1469-7580.2008.00963.x Jonusiene, 2013, Down-regulated expression of Notch signaling molecules in human endometrial cancer, Med Oncol, 30, 438, 10.1007/s12032-012-0438-y Takebe, 2014, Targeting Notch signaling pathway in cancer: clinical development advances challenges, Pharmacol Ther, 141, 140, 10.1016/j.pharmthera.2013.09.005 Rizzo, 2008, Rational targeting of Notch signaling in cancer, Oncogene, 27, 5124, 10.1038/onc.2008.226 Schott, 2013, Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors, Clin Cancer Res, 19, 1512, 10.1158/1078-0432.CCR-11-3326 Mori, 2012, Effects of N-[N-(3, 5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester (DAPT) on cell proliferation and apoptosis in Ishikawa endometrial cancer cells, Hum Cell, 25, 9, 10.1007/s13577-011-0038-8 Lewis, 2007, Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling, Chem Biol, 14, 209, 10.1016/j.chembiol.2006.12.010 Mizuma, 2012, The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models, Mol Cancer Ther, 11, 1999, 10.1158/1535-7163.MCT-12-0017 Ramakrishnan, 2012, MRK003, a gamma-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma, Leukemia, 26, 340, 10.1038/leu.2011.192 Morgan, 2009, Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma, Gynecol Oncol, 114, 293, 10.1016/j.ygyno.2009.04.036 English, 2013, HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor, Gynecol Oncol, 131, 753, 10.1016/j.ygyno.2013.08.033 Curley, 2009, CD133 expression defines a tumor initiating cell population in primary human ovarian cancer, Stem Cells, 27, 2875, 10.1002/stem.236 Pfaffl, 2001, A new mathematical model for relative quantification in real-time RT-PCR, Nucleic Acids Res, 29, e45, 10.1093/nar/29.9.e45 Wang, 2010, Notch1 expression correlates with tumor differentiation status in ovarian carcinoma, Med Oncol, 27, 1329, 10.1007/s12032-009-9384-8 Armstrong, 2006, Intraperitoneal cisplatin and paclitaxel in ovarian cancer, N Engl J Med, 354, 34, 10.1056/NEJMoa052985 Konishi, 2007, Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers, Cancer Res, 67, 8051, 10.1158/0008-5472.CAN-07-1022 Fouladi, 2011, Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study, J Clin Oncol, 29, 3529, 10.1200/JCO.2011.35.7806 Krop, 2012, Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors, J Clin Oncol, 30, 2307, 10.1200/JCO.2011.39.1540 Pannuti, 2010, Targeting Notch to target cancer stem cells, Clin Cancer Res, 16, 3141, 10.1158/1078-0432.CCR-09-2823 Slomovitz, 2004, Her-2/neu overexpression and amplification in uterine papillary serous carcinoma, J Clin Oncol, 22, 3126, 10.1200/JCO.2004.11.154 Santin, 2005, Determination of HER2/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization, Gynecol Oncol, 98, 24, 10.1016/j.ygyno.2005.03.041 Odicino, 2008, HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization, Int J Gynecol Cancer, 18, 14, 10.1111/j.1525-1438.2007.00946.x Pandya, 2011, Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence, Br J Cancer, 105, 796, 10.1038/bjc.2011.321 Osipo, 2008, ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor, Oncogene, 27, 5019, 10.1038/onc.2008.149